 |
PDBsum entry 3fvh
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Cell cycle, peptide binding protein
|
PDB id
|
|
|
|
3fvh
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.21
- polo kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Struct Biol
16:876-882
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
|
|
S.M.Yun,
T.Moulaei,
D.Lim,
J.K.Bang,
J.E.Park,
S.R.Shenoy,
F.Liu,
Y.H.Kang,
C.Liao,
N.K.Soung,
S.Lee,
D.Y.Yoon,
Y.Lim,
D.H.Lee,
A.Otaka,
E.Appella,
J.B.McMahon,
M.C.Nicklaus,
T.R.Burke,
M.B.Yaffe,
A.Wlodawer,
K.S.Lee.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Polo-like kinase-1 (Plk1) has a pivotal role in cell proliferation and is
considered a potential target for anticancer therapy. The noncatalytic polo-box
domain (PBD) of Plk1 forms a phosphoepitope binding module for protein-protein
interaction. Here, we report the identification of minimal phosphopeptides that
specifically interact with the PBD of human PLK1, but not those of the closely
related PLK2 and PLK3. Comparative binding studies and analyses of crystal
structures of the PLK1 PBD in complex with the minimal phosphopeptides revealed
that the C-terminal SpT dipeptide functions as a high-affinity anchor, whereas
the N-terminal residues are crucial for providing specificity and affinity to
the interaction. Inhibition of the PLK1 PBD by phosphothreonine mimetic peptides
was sufficient to induce mitotic arrest and apoptotic cell death. The mode of
interaction between the minimal peptide and PBD may provide a template for
designing therapeutic agents that target PLK1.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
(a–c) Various lengths of N-terminal Cys-(CH[2])[6]–fused
Thr78 peptides were cross-linked to beads (a) and then tested
for their ability to precipitate PLK1 from mitotic HeLa lysates.
The phosphorylated Thr78 residue ('T' in red) and the invariable
Ser77 residue ('S' in blue) crucial for PBD binding are
indicated in a (above right). Immunoblots with antibody to PLK1
show levels of PLK1 coprecipitated with the indicated peptides.
A shortened form of the synthetic peptide optimized for PLK1 PBD
binding (MQSpTPL)^13 was included for comparison. Numbers
indicate efficiency of PLK1 precipitation by each peptide
relative to the PLK1 signal in the input. (d) A 6-mer Thr78
peptide (LHSpTAI) analogous to the synthetic optimal peptide
(MQSpTPL) was tested for PLK1 binding as in a–c.
|
 |
Figure 3.
(a) Superposition of phosphopeptide binding pockets of
PBD^PL, PBD^PP, PBD^S+G and PBD^S. Gray, PBD; green, PLHSpT;
yellow, PLHSpT-associated glycerol molecule; cyan, PPHSpT;
magenta, glycerol molecule (two half-occupancy conformations at
Ser–1 position) of PBD^S+G; black, two sulfate anions of
PBD^S+G and PBD^S (red, oxygen atoms). Differences in exact
positions of sulfate and phosphate groups could result from the
fact that sulfate is a free anion, whereas phosphate is
covalently linked to the phosphopeptide. (b) PBD residues
involved in binding of PLHSpT are labeled and shown in cyan. All
water molecules that form an interface between the
phosphopeptide and PBD are drawn in red mesh. (c) Superposition
of PLHSpT (green), PPHSpT (cyan), MQSpTPL (magenta) and PMQSpTPL
(gray). (d,e) Mixture of HeLa lysates expressing kinase-inactive
Flag-PLK1(K82M), Flag-PLK2(K108M) or Flag-PLK3(K52R) was
subjected to pull-down assays as in Figure 2a, with the
indicated 5-mer wild-type (PLHSpT) and mutants cross-linked to
beads. The nonphosphorylated Thr78 peptide PLHST was used as a
control. Numbers above the blot indicate relative efficiency of
PLK2 precipitation; numbers below denote relative efficiency of
PLK1 precipitation. (f) Nature of interactions between
SpT-containing peptides and PLK1 PBD. Alignment of minimal p-T78
peptides (PLHST and LHSTA) and synthetic optimal peptides
(PMQSTPL and MQSTPL) are shown. See text for details.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2009,
16,
876-882)
copyright 2009.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Stein,
and
P.Aloy
(2010).
Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures.
|
| |
PLoS Comput Biol,
6,
e1000789.
|
 |
|
|
|
|
 |
C.Liao,
J.E.Park,
J.K.Bang,
M.C.Nicklaus,
and
K.S.Lee
(2010).
Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1.
|
| |
ACS Med Chem Lett,
1,
110-114.
|
 |
|
|
|
|
 |
D.J.Huggins,
G.J.McKenzie,
D.D.Robinson,
A.J.Narváez,
B.Hardwick,
M.Roberts-Thomson,
A.R.Venkitaraman,
G.H.Grant,
and
M.C.Payne
(2010).
Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
|
| |
PLoS Comput Biol,
6,
0.
|
 |
|
|
|
|
 |
J.E.Park,
N.K.Soung,
Y.Johmura,
Y.H.Kang,
C.Liao,
K.H.Lee,
C.H.Park,
M.C.Nicklaus,
and
K.S.Lee
(2010).
Polo-box domain: a versatile mediator of polo-like kinase function.
|
| |
Cell Mol Life Sci,
67,
1957-1970.
|
 |
|
|
|
|
 |
K.Strebhardt
(2010).
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
|
| |
Nat Rev Drug Discov,
9,
643-660.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |